Patents by Inventor David Dukhan

David Dukhan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-VIRAL AND HEPATIC-TARGETED DRUGS
    Publication number: 20260144879
    Abstract: Disclosed herein are identified compound fragments, compounds and their pharmaceutically acceptable salts, isotopes or solvates, useful as antiviral drug and/or as a hepatic-targeted drug, such as for the treatment of HBV, HDV and/or HIV.
    Type: Application
    Filed: January 13, 2026
    Publication date: May 28, 2026
    Applicant: AI-BIOPHARMA
    Inventors: Cyril B. DOUSSON, David DUKHAN
  • Anti-viral and hepatic-targeted drugs
    Patent number: 12539332
    Abstract: Disclosed herein are identified compound fragments, compounds and their pharmaceutically acceptable salts, isotopes or solvates, useful as antiviral drug and/or as a hepatic-targeted drug, such as for the treatment of HBV, HDV and/or HIV. Formula (I).
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: February 3, 2026
    Assignee: A-BIOPHARMA
    Inventors: Cyril B. Dousson, David Dukhan
  • ANTI-VIRAL AND HEPATIC-TARGETED DRUGS
    Publication number: 20240139325
    Abstract: Disclosed herein are identified compound fragments, compounds and their pharmaceutically acceptable salts, isotopes or solvates, useful as antiviral drug and/or as a hepatic-targeted drug, such as for the treatment of HBV, HDV and/or HIV. Formula (I).
    Type: Application
    Filed: October 19, 2020
    Publication date: May 2, 2024
    Inventors: Cyril B. DOUSSON, David DUKHAN
  • Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
    Patent number: 11730748
    Abstract: The present invention relates to Compounds of Formula (I) or Formula (II): or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: August 22, 2023
    Assignee: MSD International GMBH
    Inventors: Cyril B. Dousson, David Dukhan, Christophe C. Parsy, Stephane L. Bogen
  • CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20220040214
    Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Derivative, and methods of using the Cyclic Phosphate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: October 7, 2021
    Publication date: February 10, 2022
    Applicants: MSD International GMBH, MSD International GMBH
    Inventors: Stephane Bogen, David Dukhan, Francois-Rene Alexandre, Rachid Rahali, Christophe Claude Parsy, Julien Milhau, Claire Pierra Rouviere, Cyril B. Dousson
  • CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES
    Publication number: 20210205339
    Abstract: The present invention relates to Compounds of Formula (I) or Formula (II): or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.
    Type: Application
    Filed: November 24, 2020
    Publication date: July 8, 2021
    Applicant: MSD International GMBH
    Inventors: Cyril B. Dousson, David Dukhan, Christophe C. Parsy, Stephane L. Bogen
  • Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
    Patent number: 10899788
    Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 26, 2021
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Stephane Bogen, David Dukhan, Guillaume Brandt, Claire Pierra Rouviere, Cyril B. Dousson, Francois-Rene Alexandre
  • Nucleotides for the treatment of cancer
    Patent number: 10815264
    Abstract: The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: October 27, 2020
    Assignee: Southern Research Institute
    Inventors: Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Christophe C. Parsy
  • Nucleotides for the treatment of cancer
    Patent number: 10766917
    Abstract: The present invention relates to novel nucleoside derivatives, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: September 8, 2020
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: Cyril B. Dousson, David Dukhan, Christophe Claude Parsy
  • Antiviral aryl-amide phosphodiamide compounds
    Patent number: 10736908
    Abstract: Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: August 11, 2020
    Assignees: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLC
    Inventors: Jean-Laurent Paparin, Houcine Rahali, Aurélien Salanson, Daniel Da Costa, David Dukhan, Timothy J. Hartingh, Izzat Raheem, John Schreier
  • D-amino acid compounds for liver disease
    Patent number: 10717758
    Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: July 21, 2020
    Assignee: IDENIX PHARMACEUTICALS LLC
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart, David Dukhan
  • 4?-or nucleosides for the treatment of HCV
    Patent number: 10683321
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 4?-OR nucleosides of Formula I: or a pharmaceutically acceptable salt thereof, wherein Base, PD, R, Z1, Z2, Z3, and Z4 are as defined herein.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: June 16, 2020
    Assignee: Idenix Pharmaceuticals LLC
    Inventors: David Dukhan, Cyril B. Dousson, Adel M. Moussa, Benjamin Alexander Mayes, Alistair James Stewart
  • CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20200179428
    Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Q, V, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Derivative, and methods of using the Cyclic Phosphate Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: June 20, 2017
    Publication date: June 11, 2020
    Applicants: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLC
    Inventors: STEPHANE BOGEN, David DUKHAN, Francois-Rene ALEXANDRE, Rachid RAHALI, Christophe PARSY, Jullen MILHAU, Claire Pierra ROUVIERE, Cyril B. DOUSSON
  • Antiviral aliphatic ester prodrugs of tenofovir
    Patent number: 10519159
    Abstract: Compounds of Formula I: and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: December 31, 2019
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals, LLC.
    Inventors: Jean-Laurent Paparin, Izzat Raheem, Houcine Rahali, Daniel Da Costa, David Dukhan
  • CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES
    Publication number: 20190365788
    Abstract: The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.
    Type: Application
    Filed: November 15, 2017
    Publication date: December 5, 2019
    Applicant: IDENIX PHARMACEUTICALS LLC
    Inventors: Cyril Dousson, David Dukhan, Christophe C. Parsy, Stephane L. Bogen
  • Antiviral prodrugs of tenofovir
    Patent number: 10449208
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: October 22, 2019
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC.
    Inventors: Daniel Da Costa, Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Houcine Rahali, Izzat Raheem
  • ANTIVIRAL ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS
    Publication number: 20190262365
    Abstract: Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 29, 2019
    Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC.
    Inventors: Jean-Laurent Paparin, Houcine Rahali, Aurélien Salanson, Daniel Da Costa, David Dukhan, Timothy J. Hartingh, Izzat Raheem, John Schreier
  • CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20190233463
    Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.
    Type: Application
    Filed: June 20, 2017
    Publication date: August 1, 2019
    Applicants: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLC
    Inventors: Stephane BOGEN, David DUKHAN, Guillaume BRANDT, Claire Pierra ROUVIERE, Cyril B. DOUSSON, Francois-Rene ALEXANDRE
  • USE OF CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVESFOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20190192548
    Abstract: The present invention relates to methods of treating or preventing a viral infection using Compounds of Formula (I); or a pharmaceutically acceptable salt thereof, wherein A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Compound of Formula (I).
    Type: Application
    Filed: June 20, 2017
    Publication date: June 27, 2019
    Applicants: MERCK SHARP & DOHME CORP., IDENIX PHARMACEUTICALS LLC
    Inventors: Stephane BOGEN, David DUKHAN, Cyril B. DOUSSON, Christophe Claude PARSY
  • ANTIVIRAL PRODRUGS OF TENOFOVIR
    Publication number: 20190183912
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and co-crystals thereof are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: August 22, 2017
    Publication date: June 20, 2019
    Applicants: Merck Sharp & Dohme Corp., IDENIX PHARMACEUTICALS LLC
    Inventors: Daniel Da Costa, Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Houcine Rahali, Izzat Raheem